Kodiak Sciences Inc. (NASDAQ:KOD) changed 2.29% to recent value of $43.72. The stock transacted 332944 shares during most recent day however it has an average volume of 416.84K shares. It spotted trading -47.17% off 52-week high price. On the other end, the stock has been noted 646.08% away from the low price over the last 52-weeks.
On April 2, 2020, Kodiak Sciences Inc. (NASDAQ:KOD) a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, reported the appointment of Charles Bancroft to its board of directors.
Charlie recently retired from a successful career at Bristol Myers Squibb (BMS) where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held numerous roles of increasing responsibility. He served as Chief Financial Officer from 2010 to 2019 and was appointed Executive Vice President, Head of Integration and Strategy & Business Development in 2019. He received his bachelor’s degree in accounting from Drexel University and his M.B.A. in finance from Temple University.
Charlie served as a member of the board of Colgate-Palmolive Company from 2017 to March 2020. He was appointed to GlaxoSmithKline’s board of directors as a Non-Executive Director in March 2020.
Its earnings per share (EPS) expected to touch remained -11.40% for this year while earning per share for the next 5-years is expected to reach at 12.40%.
The company has 45.27M of outstanding shares and 31.59M shares were floated in the market. According to the most recent quarter its current ratio was 29 that represents company’s ability to meet its current financial obligations. The price moved ahead of -11.81% from the mean of 20 days, -24.67% from mean of 50 days SMA and performed 24.36% from mean of 200 days price. Company’s performance for the week was -10.32%, -37.11% for month and YTD performance remained -39.24%.